<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font19 { font-size : 19; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font25">the </span>
   <span class="font19">with </span>
   <span class="font17">for </span>
   <span class="font15">patients </span>
   <span class="font15">COVIDâ€� </span>
   <span class="font14">al. </span>
   <span class="font14">;:â€". </span>
   <span class="font13">risk </span>
   <span class="font13">from </span>
   <span class="font13">IBD </span>
   <span class="font13">are </span>
   <span class="font12">infection </span>
   <span class="font12">should </span>
   <span class="font12">has </span>
   <span class="font12">increased </span>
   <span class="font12">that </span>
   <span class="font12">have </span>
   <span class="font12">may </span>
   <span class="font11">infections </span>
   <span class="font11">treatment </span>
   <span class="font11">been </span>
   <span class="font11">patient </span>
   <span class="font11">days </span>
   <span class="font11">disease </span>
   <span class="font11">inflammatory </span>
   <span class="font11">respiratory </span>
   <span class="font11">compared </span>
   <span class="font11">{background </span>
   <span class="font11">clinical </span>
   <span class="font11">placebo </span>
   <span class="font11">bowel </span>
   <span class="font11">not </span>
   <span class="font11">â†‘ </span>
   <span class="font11">SARSâ€�CoVâ€� </span>
   <span class="font11">viral </span>
   <span class="font11">The </span>
   <span class="font11">can </span>
   <span class="font11">fees </span>
   <span class="font11">personal </span>
   <span class="font11">COVIDâ€�, </span>
   <span class="font11">associated </span>
   <span class="font11">medications </span>
   <span class="font11">severe </span>
   <span class="font11">disease. </span>
   <span class="font11">margin </span>
   <span class="font11">there </span>
   <span class="font11">this </span>
   <span class="font11">was </span>
   <span class="font11">{border-style </span>
   <span class="font11">coronavirus </span>
   <span class="font10">consider </span>
   <span class="font10">px;} </span>
   <span class="font10">review </span>
   <span class="font10">used </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">Clinical </span>
   <span class="font10">also </span>
   <span class="font10">being </span>
   <span class="font10">effect </span>
   <span class="font10">.â€�.) </span>
   <span class="font10">after </span>
   <span class="font10">management </span>
   <span class="font10">virus </span>
   <span class="font10">Clin </span>
   <span class="font10">Dis. </span>
   <span class="font10">corticosteroids </span>
   <span class="font10">drug </span>
   <span class="font10">factors </span>
   <span class="font10">health </span>
   <span class="font10">public </span>
   <span class="font10">reduce </span>
   <span class="font10">where </span>
   <span class="font10">Med. </span>
   <span class="font10">any </span>
   <span class="font10">dose </span>
   <span class="font10">serious </span>
   <span class="font10">symptoms </span>
   <span class="font10">systematic </span>
   <span class="font10">therapy </span>
   <span class="font10">tract </span>
   <span class="font10">COVIDâ€�. </span>
   <span class="font10">This </span>
   <span class="font10">acute </span>
   <span class="font10">but </span>
   <span class="font10">increase </span>
   <span class="font10">novel </span>
   <span class="font10">possible </span>
   <span class="font10">these </span>
   <span class="font10">tofacitinib </span>
   <span class="font10">transmission </span>
   <span class="font10">contact </span>
   <span class="font10">eliminated </span>
   <span class="font10">influenza </span>
   <span class="font10">mortality </span>
   <span class="font10">potential </span>
   <span class="font10">significant </span>
   <span class="font10">systemic </span>
   <span class="font10">their </span>
   <span class="font10">who </span>
   <span class="font10">;:. </span>
   <span class="font10">analysis </span>
   <span class="font10">drugs </span>
   <span class="font10">evidence </span>
   <span class="font10">its </span>
   <span class="font10">safety </span>
   <span class="font10">through </span>
   <span class="font10">use </span>
   <span class="font10">which </span>
   <span class="font10">CYPA </span>
   <span class="font10">Crohn's </span>
   <span class="font10">March </span>
   <span class="font10">Pharmacol </span>
   <span class="font10">Risk </span>
   <span class="font10">gastrointestinal </span>
   <span class="font10">low </span>
   <span class="font10">research </span>
   <span class="font10">therapies </span>
   <span class="font10">they </span>
   <span class="font10">those </span>
   <span class="font10">ulcerative </span>
   <span class="font10">were </span>
   <span class="font10">Aliment </span>
   <span class="font10">Chinese </span>
   <span class="font10">Ther. </span>
   <span class="font10">There </span>
   <span class="font10">Tofacitinib </span>
   <span class="font10">available </span>
   <span class="font10">considered </span>
   <span class="font10">develops </span>
   <span class="font10">duration </span>
   <span class="font10">grants </span>
   <span class="font10">including </span>
   <span class="font10">infected </span>
   <span class="font10">infection. </span>
   <span class="font10">lower </span>
   <span class="font10">maintenance </span>
   <span class="font10">metaâ€�analysis. </span>
   <span class="font10">more </span>
   <span class="font10">patients. </span>
   <span class="font10">pneumonia </span>
   <span class="font10">reported </span>
   <span class="font10">time </span>
   <span class="font10">trial </span>
   <span class="font10">when </span>
   <span class="font10">Can </span>
   <span class="font10">Day </span>
   <span class="font10">Engl </span>
   <span class="font10">Gastroenterol. </span>
   <span class="font10">Metabolised </span>
   <span class="font10">RNA </span>
   <span class="font10">antiâ€�TNF </span>
   <span class="font10">article </span>
   <span class="font10">before </span>
   <span class="font10">cases </span>
   <span class="font10">cell </span>
   <span class="font10">collab: </span>
   <span class="font10">data </span>
   <span class="font10">day </span>
   <span class="font10">disease: </span>
   <span class="font10">effects </span>
   <span class="font10">medical </span>
   <span class="font10">medication </span>
   <span class="font10">opportunistic </span>
   <span class="font10">px; </span>
   <span class="font10">received </span>
   <span class="font10">reports </span>
   <span class="font10">rheumatoid </span>
   <span class="font10">therapeutic </span>
   <span class="font10">twice </span>
   <span class="font10">withholding </span>
   <span class="font10">years </span>
   <span class="font10">{font-family </span>
   <span class="font10">â†" </span>
   <span class="font10">â€�Â </span>
   <span class="font10">Avoid </span>
   <span class="font10">Colitis. </span>
   <span class="font10">Coronavirus </span>
   <span class="font10">Corticosteroids </span>
   <span class="font10">Crohns </span>
   <span class="font10">Disease </span>
   <span class="font10">Health </span>
   <span class="font10">Infect </span>
   <span class="font10">NCT </span>
   <span class="font10">Table </span>
   <span class="font10">URTI </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">adverse </span>
   <span class="font10">age </span>
   <span class="font10">and/or </span>
   <span class="font10">appear </span>
   <span class="font10">avoid </span>
   <span class="font10">between </span>
   <span class="font10">current </span>
   <span class="font10">currently </span>
   <span class="font10">developing </span>
   <span class="font10">font-size </span>
   <span class="font10">healthcare </span>
   <span class="font10">immune </span>
   <span class="font10">immunosuppressive </span>
   <span class="font10">implications </span>
   <span class="font10">induction </span>
   <span class="font10">infusion </span>
   <span class="font10">interactions </span>
   <span class="font10">lung </span>
   <span class="font10">made </span>
   <span class="font10">manuscript. </span>
   <span class="font10">most </span>
   <span class="font10">occur </span>
   <span class="font10">other </span>
   <span class="font10">outbreak </span>
   <span class="font10">positive </span>
   <span class="font10">rates </span>
   <span class="font10">remission </span>
   <span class="font10">secondary </span>
   <span class="font10">study </span>
   <span class="font10">study. </span>
   <span class="font10">syndrome </span>
   <span class="font10">than </span>
   <span class="font10">vedolizumab </span>
   <span class="font10">will </span>
   <span class="font10">within </span>
   <span class="font10">&amp;amp; </span>
   <span class="font10">CI: </span>
   <span class="font10">COVID- </span>
   <span class="font10">CYP </span>
   <span class="font10">CYPA, </span>
   <span class="font10">CYPC, </span>
   <span class="font10">Central </span>
   <span class="font10">China. </span>
   <span class="font10">Chloroquine </span>
   <span class="font10">ClinicalTrials.gov </span>
   <span class="font10">Despite </span>
   <span class="font10">However, </span>
   <span class="font10">Human </span>
   <span class="font10">Identifier: </span>
   <span class="font10">Int </span>
   <span class="font10">JAK </span>
   <span class="font10">Ltd, </span>
   <span class="font10">MERSâ€�CoV </span>
   <span class="font10">May </span>
   <span class="font10">Methotrexate </span>
   <span class="font10">PubMed </span>
   <span class="font10">Respiratory </span>
   <span class="font10">Review </span>
   <span class="font10">These </span>
   <span class="font10">Trials </span>
   <span class="font10">Where </span>
   <span class="font10">Wiley </span>
   <span class="font10">acknowledgement </span>
   <span class="font10">against </span>
   <span class="font10">biologic </span>
   <span class="font10">budesonide </span>
   <span class="font10">by: </span>
   <span class="font10">clearance </span>
   <span class="font10">clinically </span>
   <span class="font10">colitis: </span>
   <span class="font10">concern </span>
   <span class="font10">course </span>
   <span class="font10">daily </span>
   <span class="font10">death </span>
   <span class="font10">develop </span>
   <span class="font10">does </span>
   <span class="font10">double; </span>
   <span class="font10">due </span>
   <span class="font10">emergency </span>
   <span class="font10">emergency. </span>
   <span class="font10">following </span>
   <span class="font10">form </span>
   <span class="font10">freely </span>
   <span class="font10">had </span>
   <span class="font10">hours </span>
   <span class="font10">human </span>
   <span class="font10">hydroxychloroquine </span>
   <span class="font10">increases </span>
   <span class="font10">inflammation </span>
   <span class="font10">into </span>
   <span class="font10">levels </span>
   <span class="font10">lopinavir/ritonavir </span>
   <span class="font10">means </span>
   <span class="font10">methotrexate </span>
   <span class="font10">monitor </span>
   <span class="font10">need </span>
   <span class="font10">original </span>
   <span class="font10">pandemic </span>
   <span class="font10">part </span>
   <span class="font10">patients, </span>
   <span class="font10">patientâ€�years </span>
   <span class="font10">re-use </span>
   <span class="font10">regarding </span>
   <span class="font10">response. </span>
   <span class="font10">risks </span>
   <span class="font10">shown </span>
   <span class="font10">source, </span>
   <span class="font10">steroids </span>
   <span class="font10">testing </span>
   <span class="font10">thiopurine </span>
   <span class="font10">treat </span>
   <span class="font10">trials </span>
   <span class="font10">unrestricted </span>
   <span class="font10">until </span>
   <span class="font10">ustekinumab </span>
   <span class="font10">(%), </span>
   <span class="font10">(C) </span>
   <span class="font10">Bowel </span>
   <span class="font10">Budesonide </span>
   <span class="font10">COVIDâ€�: </span>
   <span class="font10">Consider </span>
   <span class="font10">Inhibits: </span>
   <span class="font10">John </span>
   <span class="font10">Lancet. </span>
   <span class="font10">Patients </span>
   <span class="font10">Prevention </span>
   <span class="font10">Remdesivir </span>
   <span class="font10">Rev. </span>
   <span class="font10">Severe </span>
   <span class="font10">Sons, </span>
   <span class="font10">Syndrome </span>
   <span class="font10">Use </span>
   <span class="font10">absorption </span>
   <span class="font10">active </span>
   <span class="font10">agent </span>
   <span class="font10">agents </span>
   <span class="font10">although </span>
   <span class="font10">among </span>
   <span class="font10">article: </span>
   <span class="font10">bioavailability </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">care </span>
   <span class="font10">case </span>
   <span class="font10">characteristics </span>
   <span class="font10">combination </span>
   <span class="font10">common </span>
   <span class="font10">complications </span>
   <span class="font10">corticosteroid </span>
   <span class="font10">demonstrated </span>
   <span class="font10">diagnosis </span>
   <span class="font10">efficacy </span>
   <span class="font10">elimination </span>
   <span class="font10">events </span>
   <span class="font10">first </span>
   <span class="font10">followâ€�up </span>
   <span class="font10">given </span>
   <span class="font10">hospital </span>
   <span class="font10">hour </span>
   <span class="font10">illness </span>
   <span class="font10">immunocompromised </span>
   <span class="font10">increasing </span>
   <span class="font10">infliximab </span>
   <span class="font10">initial </span>
   <span class="font10">known </span>
   <span class="font10">levels, </span>
   <span class="font10">onset </span>
   <span class="font10">over </span>
   <span class="font10">overall </span>
   <span class="font10">per </span>
   <span class="font10">pharmacokinetics </span>
   <span class="font10">protein </span>
   <span class="font10">requiring </span>
   <span class="font10">served </span>
   <span class="font10">severity </span>
   <span class="font10">shedding </span>
   <span class="font10">solid; </span>
   <span class="font10">studies </span>
   <span class="font10">symptom </span>
   <span class="font10">system </span>
   <span class="font10">therefore </span>
   <span class="font10">thiopurines </span>
   <span class="font10">vitamin </span>
   <span class="font10">well </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">â€� </span>
   <span class="font10">&amp;gt;Â </span>
   <span class="font10">(.%) </span>
   <span class="font10">(COVIDâ€�) </span>
   <span class="font10">(GSâ€�) </span>
   <span class="font10">ACE </span>
   <span class="font10">Abbvie, </span>
   <span class="font10">Absorbed </span>
   <span class="font10">Agents. </span>
   <span class="font10">Antimicrob </span>
   <span class="font10">Britt </span>
   <span class="font10">ChiCTR </span>
   <span class="font10">China: </span>
   <span class="font10">Control </span>
   <span class="font10">Daily </span>
   <span class="font10">Drug </span>
   <span class="font10">FeaganBG, </span>
   <span class="font10">Finally, </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Gastroenterology. </span>
   <span class="font10">IBD, </span>
   <span class="font10">ID: </span>
   <span class="font10">Immunomodulators </span>
   <span class="font10">Inflamm </span>
   <span class="font10">Organisation </span>
   <span class="font10">Pharmacokinet. </span>
   <span class="font10">Registry </span>
   <span class="font10">SARSâ€�CoVâ€�, </span>
   <span class="font10">SARSâ€�CoVâ€�. </span>
   <span class="font10">Safety </span>
   <span class="font10">Therefore, </span>
   <span class="font10">Thiopurines </span>
   <span class="font10">Ustekinumab </span>
   <span class="font10">World </span>
   <span class="font10">across </span>
   <span class="font10">addition, </span>
   <span class="font10">all </span>
   <span class="font10">antiâ€�inflammatory </span>
   <span class="font10">antiâ€�viral </span>
   <span class="font10">appears </span>
   <span class="font10">appropriate </span>
   <span class="font10">assessment </span>
   <span class="font10">beclomethasone </span>
   <span class="font10">binding </span>
   <span class="font10">bold </span>
   <span class="font10">both </span>
   <span class="font10">causing </span>
   <span class="font10">cells </span>
   <span class="font10">chloroquine </span>
   <span class="font10">ciclosporin </span>
   <span class="font10">colitis </span>
   <span class="font10">concentration </span>
   <span class="font10">confirmed </span>
   <span class="font10">continue </span>
   <span class="font10">control </span>
   <span class="font10">controlled </span>
   <span class="font10">coronaviruses </span>
   <span class="font10">corticosteroids, </span>
   <span class="font10">corticosteroids. </span>
   <span class="font10">courier; </span>
   <span class="font10">critically </span>
   <span class="font10">cytokines </span>
   <span class="font10">demonstrate </span>
   <span class="font10">diabetes </span>
   <span class="font10">digestive </span>
   <span class="font10">distancing </span>
   <span class="font10">during </span>
   <span class="font10">effective </span>
   <span class="font10">em; </span>
   <span class="font10">emerged </span>
   <span class="font10">encouraged </span>
   <span class="font10">even </span>
   <span class="font10">exposure </span>
   <span class="font10">found </span>
   <span class="font10">general </span>
   <span class="font10">global </span>
   <span class="font10">greater </span>
   <span class="font10">group </span>
   <span class="font10">high </span>
   <span class="font10">highly </span>
   <span class="font10">hospitalisation </span>
   <span class="font10">hospitalized </span>
   <span class="font10">host </span>
   <span class="font10">include </span>
   <span class="font10">infections, </span>
   <span class="font10">infusions </span>
   <span class="font10">inhibitors </span>
   <span class="font10">isolation </span>
   <span class="font10">jejunum: </span>
   <span class="font10">kg: </span>
   <span class="font10">literature </span>
   <span class="font10">longâ€�term </span>
   <span class="font10">many </span>
   <span class="font10">median </span>
   <span class="font10">metabolism </span>
   <span class="font10">metaâ€�analysis </span>
   <span class="font10">mg/kg </span>
   <span class="font10">mild </span>
   <span class="font10">min. </span>
   <span class="font10">multiple </span>
   <span class="font10">myelosuppression </span>
   <span class="font10">network </span>
   <span class="font10">number </span>
   <span class="font10">ok; </span>
   <span class="font10">one </span>
   <span class="font10">options </span>
   <span class="font10">pharmacy </span>
   <span class="font10">possible, </span>
   <span class="font10">potentially </span>
   <span class="font10">predominantly </span>
   <span class="font10">present </span>
   <span class="font10">primary </span>
   <span class="font10">product </span>
   <span class="font10">profile </span>
   <span class="font10">prolonged </span>
   <span class="font10">protease </span>
   <span class="font10">pt;} </span>
   <span class="font10">pulmonary </span>
   <span class="font10">rapid </span>
   <span class="font10">recent </span>
   <span class="font10">reduced </span>
   <span class="font10">reduction </span>
   <span class="font10">remain </span>
   <span class="font10">remains </span>
   <span class="font10">require </span>
   <span class="font10">required </span>
   <span class="font10">resolution </span>
   <span class="font10">results </span>
   <span class="font10">revision </span>
   <span class="font10">risk. </span>
   <span class="font10">setting </span>
   <span class="font10">side </span>
   <span class="font10">significance </span>
   <span class="font10">similar </span>
   <span class="font10">small </span>
   <span class="font10">social </span>
   <span class="font10">someone </span>
   <span class="font10">subcutaneous </span>
   <span class="font10">suggest </span>
   <span class="font10">symptoms. </span>
   <span class="font10">three </span>
   <span class="font10">treatments </span>
   <span class="font10">trial. </span>
   <span class="font10">trials. </span>
   <span class="font10">upper </span>
   <span class="font10">very </span>
   <span class="font10">via </span>
   <span class="font10">viruses </span>
   <span class="font10">weeks. </span>
   <span class="font10">workers </span>
   <span class="font10">â‰¥Â </span>
   <span class="font10">â€�: </span>
   <span class="font10">â€�ASA </span>
  </p>
 </body>
</html>
